Tyrosine Kinase Inhibitor Discontinuation Can Toughen CML Outcomes
NEW YORK (Reuters Well being) – In patients with power myeloid leukemia (CML), discontinuing tyrosine kinase inhibitor (TKI) therapy is staunch and connected to better patient-reported outcomes, a nonrandomized trial displays. “Clutch into consideration therapy discontinuation in CML patients who…